Sun Pharma: Difference between revisions

What links here Related changes Page information Get shortened URL
Created by DaxServer
Last edited June 10, 2022
VisualWikitext
imported>DaxServer
m Add back cat per discussion WP:TCAT using Pywikibot category add
 
UpdateBot (talk | contribs)
Bots
22,126 edits
robot: Update article (please report if you notice any mistake or error in this edit)
 
Line 4: Line 4:
| name = Sun Pharmaceutical Industries Limited
| name = Sun Pharmaceutical Industries Limited
| logo = Sun Pharma logo.svg
| logo = Sun Pharma logo.svg
| logo_size = 175px
| logo_size = 120px
| image = Sun Pharma HQ.png
| image_size = 250px
| image_caption = Sun Pharma headquarters in [[Mumbai]], [[India]]
| type = [[Public company|Public]]
| type = [[Public company|Public]]
| traded_as = {{Unbulleted list|{{BSE|524715}}|{{NSE|SUNPHARMA}}|
| traded_as = {{Unbulleted list|{{BSE|524715}}|{{NSE|SUNPHARMA}}|
[[BSE SENSEX|BSE SENSEX Constituent]]|[[NIFTY 50|NSE NIFTY 50 Constituent]]}}
[[BSE SENSEX|BSE SENSEX Constituent]]|[[NIFTY 50|NSE NIFTY 50 Constituent]]}}
| ISIN = INE044A01036
| ISIN = INE044A01036
| hq_location_city = [[Mumbai]]
| hq_location_country = [[India]]
| area_served = Worldwide
| area_served = Worldwide
| key_people = [[Dilip Shanghvi]] (CEO)
| key_people = Dilip Shanghvi (MD)
| industry = [[Pharmaceutical industry|Pharmaceuticals]]
| industry = [[Pharmaceutical industry|Pharmaceuticals]]
| products = {{hlist|[[Pharmaceutical]]s |[[generic drug]]s |[[over-the-counter drug]]s |[[vaccine]]s |[[Medical diagnosis|diagnostics]] |[[contact lens]]es |[[Veterinary medicine|animal health]] }}
| products = {{hlist|[[Pharmaceutical]]s |[[Branded generic drug]]s |[[over-the-counter drug]]s |[[Speciality drug]]s | |[[Over-the-counter drug|OTC]]s |[[API]]s |[[Antiviral drug|ARVs]] }}
| revenue = {{profit}} {{INRConvert|334.73|b}} (2020)<ref name=finance>{{cite web|url=https://www.sunpharma.com/sites/default/files/annual/SunPharmaAR2019-20.pdf|title=Sun Pharmaceutical Annual Report 2020|publisher=Sun Pharmaceutical Limited|access-date=2 July 2019}}</ref>
| revenue = {{profit}} {{INRConvert|343337|m}}
| operating_income = {{profit}} {{INRConvert|50.10|b}} (2020)<ref name=finance/>
| revenue_year = 2021
| net_income = {{profit}} {{INRConvert|37.65|b}} (2020)<ref name=finance/>
| operating_income = {{profit}} {{INRConvert|334981|m}}
| assets = {{profit}} {{INRConvert|682.52|b}} (2020)<ref name=finance/>
| income_year = 2021
| equity = {{profit}} {{INRConvert|491.25|b}} (2020)<ref name=finance/>
| net_income = {{profit}} {{INRConvert|29038|m}}
| net_income_year = 2021
| assets = {{profit}} {{INRConvert|142965|m}}
| assets_year = 2021
| equity = {{profit}} {{INRConvert|2399|m}}
| equity_year = 2021
| owner =  
| owner =  
| num_employees = 36,000 (2020)<ref name=finance/>
| num_employees = 37,000+
| homepage = {{URL|http://www.sunpharma.com}}
| num_employees_year = 2021
| website = {{URL|https://sunpharma.com/}}
| founder = [[Dilip Shanghvi]]
| founder = [[Dilip Shanghvi]]
| foundation = {{start date and age|1983}}
| founded = {{start date and age|1983}}
| location_city = [[Mumbai]], [[Maharashtra]]
| footnotes = <ref name="fy2018">{{cite web|url=http://mypharmaproducts.store/sites/default/files/SPLL-Financial-Statement-17-18.pdf |title=Sun Pharmaceutical Announces Fourth Quarter and Fiscal Year 2018 Results |publisher=Sun Pharmaceutical |website=mypharmaproducts.store |date=February 4, 2019 |access-date=February 4, 2019}}</ref><ref name="2021ar">{{cite web |title=Annual Report 2020-21 |url=https://sunpharma.com/wp-content/uploads/2021/08/Sun-Pharma-Annual-Report-2020-21-and-Notice-of-29th-AGM.pdf |publisher=Sun Pharmaceutical Industries |access-date=12 May 2022 }}</ref>
| location_country = India
| footnotes = <ref name="fy2018">{{cite web|url=http://www.sunpharma.com/sites/default/files/SPLL-Financial-Statement-17-18.pdf |title=Sun Pharmaceutical Announces Fourth Quarter and Fiscal Year 2018 Results |publisher=Sun Pharmaceutical |website=sunpharma.com |date=February 4, 2019 |access-date=February 4, 2019}}</ref>
}}
}}


'''Sun Pharmaceutical Industries Limited''' ([[Trade name|d/b/a]] Sun Pharma) is an [[India]]n [[Multinational corporation|multinational]] [[pharmaceutical]] company headquartered in [[Mumbai, Maharashtra]], that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. Sun Pharma has presence in more than 100 countries across the globe.<ref>{{Cite web|last=Banerjee|first=Avishek|title=Sun Pharma: Global Is Local|url=http://businessworld.in/article/Sun-Pharma-Global-Is-Local/27-12-2018-165598|access-date=2021-08-06|website=BW Businessworld|language=en}}</ref> It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world,<ref name="Business Standard India">{{Cite news|title=Sun Pharmaceuticals Industries Ltd.|work=Business Standard India|url=https://www.business-standard.com/company/sun-pharma-inds-4325/information/company-history|access-date=2021-08-06}}</ref> with a total revenue of over US$4.5 billion as of June 2021.<ref name="Sun Pharma Industries">{{Cite web|title=Sun Pharma Industries|url=https://www.forbes.com/companies/sun-pharma-industries/|access-date=2021-08-06|website=Forbes|language=en}}</ref> The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.<ref name="Business Standard India"/> Its API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budensonide and Carvedilol.<ref>{{Cite web|title=Sun Pharma {{!}} IBEF|url=https://www.ibef.org/industry/research-development-india/showcase/sun-pharma|access-date=2021-08-06|website=www.ibef.org}}</ref>
'''Sun Pharmaceutical Industries Limited''' ([[Trade name|d/b/a]] '''Sun Pharma''') is an Indian [[Multinational corporation|multinational]] [[pharmaceutical]] company headquartered in [[Mumbai, Maharashtra]], that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe.<ref>{{cite web|last=Banerjee|first=Avishek|title=Sun Pharma: Global Is Local|url=http://businessworld.in/article/pharma products-Global-Is-Local/27-12-2018-165598|access-date=2021-08-06|website=BW Businessworld|language=en}}</ref> It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world,<ref name="Business Standard India">{{Cite news|title=Sun Pharmaceuticals Industries Ltd.|work=Business Standard India|url=https://www.business-standard.com/company/pharma products-inds-4325/information/company-history|access-date=2021-08-06}}</ref> with a total revenue of over US$4.5 billion as of June 2021.<ref name="Sun Pharma Industries">{{cite web|title=Sun Pharma Industries|url=https://www.forbes.com/companies/pharma products-industries/|access-date=2021-08-06|website=Forbes|language=en}}</ref> The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.<ref name="Business Standard India"/> Its API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budensonide and Carvedilol.<ref>{{cite web|title=pharma products{{!}} IBEF|url=https://www.ibef.org/industry/research-development-india/showcase/pharma products|access-date=2021-08-06|website=www.ibef.org}}{{Dead link|date=May 2022|fix-attempted=yes}}</ref>


==History==
==History==


Sun Pharmaceuticals was founded by [[Dilip Shanghvi]] in 1983 in [[Vapi]], [[Gujarat]], with five products to treat [[psychiatry]] ailments. Cardiology products were introduced in 1987<ref name="sunpharma.com">{{Cite web|title=Milestones & Recognitions {{!}} Sun Pharmaceutical Industries Limited|url=https://sunpharma.com/milestones-recognitions/|access-date=2021-08-06|website=Sun Pharmaceutical Industries Ltd.|language=en-US}}</ref> followed by [[gastroenterology]] products in 1989. Today it is ranked No.1 by prescriptions with 9 different classes of doctors in<ref>{{Citation|title=Strategic solutions|date=2013-01-11|url=http://dx.doi.org/10.4324/9780080938486-27|work=Hospitality Marketing|pages=210–219|publisher=Routledge|isbn=978-0-08-093848-6|access-date=2021-08-06}}</ref> India and a market leader in cardiology, gastroenterology, ortho, diabetology, dermatology, urology, and vitamins / minerals / nutrients.<ref>{{Citation|last=Katja S|first=Ziegler|title=AWACS I (Ger)|date=April 2019|url=http://dx.doi.org/10.1093/law-mpeccol/e542.013.542|work=Max Planck Encyclopedia of Comparative Constitutional Law|publisher=Oxford University Press|access-date=2021-08-06}}</ref>
Sun Pharmaceuticals was founded by [[Dilip Shanghvi]] in 1983 in [[Vapi]], [[Gujarat]], with five products to treat [[psychiatry]] ailments. Cardiology products were introduced in 1987<ref name="sunpharma.com">{{cite web|title=Milestones & Recognitions {{!}} Sun Pharmaceutical Industries Limited|url=https://sunpharma.com/milestones-recognitions/|access-date=2021-08-06|website=Sun Pharmaceutical Industries Ltd.|language=en-US}}</ref> followed by [[gastroenterology]] products in 1989. Today it is ranked number one by prescriptions with nine different specialties of doctors in<ref>{{Citation|title=Strategic solutions|date=2013-01-11|url=http://dx.doi.org/10.4324/9780080938486-27|work=Hospitality Marketing|pages=210–219|publisher=Routledge|doi=10.4324/9780080938486-27 |isbn=978-0-08-093848-6|access-date=2021-08-06}}</ref> India and a market leader in cardiology, gastroenterology, ortho,{{Vague|date=May 2022|reason="ortho-what?"}} diabetology, dermatology, urology, vitamins, minerals, and nutrients.<ref>{{Citation|last=Katja S|first=Ziegler|title=AWACS I (Ger)|date=April 2019|url=http://dx.doi.org/10.1093/law-mpeccol/e542.013.542|encyclopedia=Max Planck Encyclopedia of Comparative Constitutional Law|publisher=Oxford University Press|doi=10.1093/law-mpeccol/e542.013.542 |access-date=2021-08-06}}</ref>


The 2014 acquisition of [[Ranbaxy]] made Sun Pharma the largest [https://www.enrico.co.in/ pharma company] in India, the largest Indian pharma company in the US, and the 4th<ref name="Business Standard India"/> largest specialty generic company globally.
The 2014 acquisition of [[Ranbaxy]] made Sun Pharma the largest [https://www.enrico.co.in/ pharma company] in India, the largest Indian pharma company in the US, and the 4th<ref name="Business Standard India"/> largest specialty generic company globally.


Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. The US is the single largest market, accounting for about 30% of the company's turnover;<ref>{{Cite web|title=US business remains Sun Pharma’s weak spot|url=https://www.fortuneindia.com/enterprise/us-business-remains-sun-pharmas-weak-spot/101421|access-date=2021-08-06|website=www.fortuneindia.com|language=en}}</ref> in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 44 globally across across India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. [[Food and Drug Administration]] (FDA).<ref>{{Cite web |url=http://www.sunpharma.com/sites/all/themes/sunpharma/images/annual/SPIL%20Feb14%20IR%20Presentation.pdf |title=Archived copy |access-date=10 April 2014 |archive-url=https://web.archive.org/web/20140413142558/http://www.sunpharma.com/sites/all/themes/sunpharma/images/annual/SPIL%20Feb14%20IR%20Presentation.pdf |archive-date=13 April 2014 |url-status=dead |df=dmy-all }}</ref>
Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. The US is the single largest market, accounting for about 30% of the company's turnover;<ref>{{cite web|title=US business remains Sun Pharma's weak spot|url=https://www.fortuneindia.com/enterprise/us-business-remains-sun-pharmas-weak-spot/101421|access-date=2021-08-06|website=www.fortuneindia.com|language=en}}</ref> in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 44 global locations in India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. [[Food and Drug Administration]] (FDA).<ref>{{cite web |url=http://www.sunpharma.com/sites/all/themes/sunpharma/images/annual/SPIL%20Feb14%20IR%20Presentation.pdf |title=Creating Lasting Value Investor Presentation - February 2014 |access-date=10 April 2014 |archive-url=https://web.archive.org/web/20140413142558/http://www.sunpharma.com/sites/all/themes/sunpharma/images/annual/SPIL%20Feb14%20IR%20Presentation.pdf |archive-date=13 April 2014 |url-status=dead |df=dmy-all }}</ref>


Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company.<ref>{{Cite journal|date=March 2019|title=Galaxy Surfactants: financial results for the quarter and nine months ended 31 Dec 2018|url=http://dx.doi.org/10.1016/j.fos.2019.03.069|journal=Focus on Surfactants|volume=2019|issue=3|pages=6|doi=10.1016/j.fos.2019.03.069|issn=1351-4210}}</ref>
Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company.<ref>{{Cite journal|date=March 2019|title=Galaxy Surfactants: financial results for the quarter and nine months ended 31 Dec 2018|url=http://dx.doi.org/10.1016/j.fos.2019.03.069|journal=Focus on Surfactants|volume=2019|issue=3|page=6|doi=10.1016/j.fos.2019.03.069|s2cid=243155570 |issn=1351-4210}}</ref>
 
Sun Pharma requested USFDA to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs) belonging to its wholly owned subsidiary Ranbaxy Laboratories.<ref>{{Cite news|url=http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-announces-voluntary-withdrawals-of-28-andas/articleshow/56076088.cms|title=sun pharma announce withdraw anda|date=20 December 2016|access-date=22 December 2016|via=economic times}}</ref>


==Acquisitions and Joint Ventures==
==Acquisitions and Joint Ventures==
Line 50: Line 57:
In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets (other than India).<ref>{{Cite news|title=Sun Pharmaceutical, Merck & Co call off 2011 JV: Sources|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharmaceutical-merck-co-call-off-2011-jv-sources/articleshow/45154170.cms?from=mdr|access-date=2021-08-06}}</ref>
In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets (other than India).<ref>{{Cite news|title=Sun Pharmaceutical, Merck & Co call off 2011 JV: Sources|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharmaceutical-merck-co-call-off-2011-jv-sources/articleshow/45154170.cms?from=mdr|access-date=2021-08-06}}</ref>


In 2012, Sun announced acquisitions of two US companies: [[DUSA Pharmaceuticals]],<ref>{{cite web|url=http://in.reuters.com/article/dusa-sunpharma-idINDEE8A70AL20121108|title=Sun Pharma to buy U.S.-based Dusa for $230 mln|work=Reuters India|access-date=2 July 2015}}</ref> a dermatology device company; and generic pharma company URL Pharma <ref>{{cite web|url=http://www.takeda.com/news/2012/20121218_5405.html|title=Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical|author=Takeda Pharmaceutical Company Limited|website=Takeda.com|access-date=2 July 2015}}</ref> In 2013, the company announced an R&D joint venture for ophthalmology with the research company, [[Intrexon]].<ref>{{cite web|url=http://investors.dna.com/phoenix.zhtml?c=249599&p=irol-newsArticle&ID=1860186&highlight=|title=Investors – Newsroom – Intrexon|website=Investors.dna.com|access-date=2 July 2015|archive-url=https://archive.today/20140410125413/http://investors.dna.com/phoenix.zhtml?c=249599&p=irol-newsArticle&ID=1860186&highlight=|archive-date=10 April 2014|url-status=dead|df=dmy-all}}</ref>
In 2012, Sun announced acquisitions of two US companies: [[DUSA Pharmaceuticals]],<ref>{{cite news|url=http://in.reuters.com/article/dusa-sunpharma-idINDEE8A70AL20121108|title=Sun Pharma to buy U.S.-based Dusa for $230 mln|work=Reuters India|date=8 November 2012 |access-date=2 July 2015}}</ref> a dermatology device company; and generic pharma company URL Pharma <ref>{{cite web|url=http://www.takeda.com/news/2012/20121218_5405.html|title=Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical|author=Takeda Pharmaceutical Company Limited|website=Takeda.com|access-date=2 July 2015}}</ref> In 2013, the company announced an R&D joint venture for ophthalmology with the research company, [[Intrexon]].<ref>{{cite web|url=http://investors.dna.com/phoenix.zhtml?c=249599&p=irol-newsArticle&ID=1860186&highlight=|title=Investors – Newsroom – Intrexon|website=Investors.dna.com|access-date=2 July 2015|archive-url=https://archive.today/20140410125413/http://investors.dna.com/phoenix.zhtml?c=249599&p=irol-newsArticle&ID=1860186&highlight=|archive-date=10 April 2014|url-status=dead|df=dmy-all}}</ref>


On 6 April 2014, Sun Pharma acquired Ranbaxy in a US$4 billion landmark transaction to create the world’s 5th largest specialty generic pharmaceutical company.<ref>{{Cite news|last=Reporter|first=B. S.|date=2014-04-08|title=Sun Pharma buys Ranbaxy from Japan's Daiichi|work=Business Standard India|url=https://www.business-standard.com/article/companies/sun-pharma-buys-ranbaxy-from-japan-s-daiichi-114040700737_1.html|access-date=2021-08-06}}</ref>
On 6 April 2014, Sun Pharma acquired [[Ranbaxy Laboratories|Ranbaxy]] in a US$4 billion landmark transaction to create the world's 5th largest specialty generic pharmaceutical company.<ref>{{Cite news|last=Reporter|first=B. S.|date=2014-04-08|title=Sun Pharma buys Ranbaxy from Japan's Daiichi|work=Business Standard India|url=https://www.business-standard.com/article/companies/sun-pharma-buys-ranbaxy-from-japan-s-daiichi-114040700737_1.html|access-date=2021-08-06}}</ref>


Then Sun Pharma entered into a licensing agreement with Merck & Co. Inc. for Tildrakizumab (MK- 3222) in order to further strengthen the specialty product pipeline.<ref>{{Cite news|title=Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-merck-co-inc-enter-into-pact-for-tildrakizumab/articleshow/42730781.cms?from=mdr|access-date=2021-08-06}}</ref>
Then Sun Pharma entered into a licensing agreement with [[Merck & Co.|Merck & Co. Inc.]] for [[Tildrakizumab]] (MK- 3222) in order to further strengthen the specialty product pipeline.<ref>{{Cite news|title=Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-merck-co-inc-enter-into-pact-for-tildrakizumab/articleshow/42730781.cms?from=mdr|access-date=2021-08-06}}</ref>


To access sterile injectable capacity in the US, it acquired Pharmalucence in the USA in the same year.<ref>{{Cite web|last=Unnikrishnan|first=C. H.|date=2014-07-16|title=Sun Pharma acquires US injectables firm Pharmalucence|url=https://www.livemint.com/Companies/hBDNNuOdQnSzaO9hWqHimK/Sun-Pharma-buys-USbased-Pharmalucence.html|access-date=2021-08-06|website=mint|language=en}}</ref>
To access sterile injectable capacity in the US, it acquired Pharmalucence in the US in the same year.<ref>{{cite web|last=Unnikrishnan|first=C. H.|date=2014-07-16|title=Sun Pharma acquires US injectables firm Pharmalucence|url=https://www.livemint.com/Companies/hBDNNuOdQnSzaO9hWqHimK/Sun-Pharma-buys-USbased-Pharmalucence.html|access-date=2021-08-06|website=mint|language=en}}</ref>


In December 2014, the Competition Commission of India approved Sun Pharma's $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.<ref>{{cite web|url=http://in.reuters.com/article/ranbaxy-lab-sun-pharma-regulator-idINKBN0JM1AY20141209|title=CCI clears Sun Pharma-Ranbaxy deal|work=Reuters India|access-date=2 July 2015}}</ref><ref name="auto">{{cite web|url=http://in.reuters.com/article/gsk-sun-pharma-deals-idINL4N0W520E20150303|title=UPDATE 1-India's Sun Pharma to buy Glaxo's opiates business in Australia|work=Reuters India|access-date=2 July 2015}}</ref>
In December 2014, the [[Competition Commission of India]] approved Sun Pharma's $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.<ref>{{cite news|url=http://in.reuters.com/article/ranbaxy-lab-sun-pharma-regulator-idINKBN0JM1AY20141209|title=CCI clears Sun Pharma-Ranbaxy deal|work=Reuters India|date=9 December 2014 |access-date=2 July 2015}}</ref><ref name="auto">{{cite news|url=http://in.reuters.com/article/gsk-sun-pharma-deals-idINL4N0W520E20150303|title=UPDATE 1-India's Sun Pharma to buy Glaxo's opiates business in Australia|work=Reuters India|date=3 March 2015 |access-date=2 July 2015}}</ref>


In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business in Australia to strengthen its pain management portfolio.<ref name="auto" />
In March 2015, Sun Pharma announced it had agreed to buy [[GlaxoSmithKline|GlaxoSmithKline's]] opiates business in Australia to strengthen its pain management portfolio.<ref name="auto" />


The following year Sun Pharma made some significant acquisitions, including 14 brands from Novartis in Japan to enter the Japanese market.<ref>{{Cite web|last=Bureau|first=Our|title=Sun Pharma acquires Novartis brands in Japan for $293 million|url=https://www.thehindubusinessline.com/companies/sun-pharma-acquires-novartis-brands-in-japan-for-293-million/article8410174.ece|access-date=2021-08-06|website=@businessline|language=en}}</ref>
The following year Sun Pharma made some significant acquisitions, including 14 brands from [[Novartis]] in Japan to enter the Japanese market.<ref>{{cite web|title=Sun Pharma acquires Novartis brands in Japan for $293 million|url=https://www.thehindubusinessline.com/companies/sun-pharma-acquires-novartis-brands-in-japan-for-293-million/article8410174.ece|access-date=2021-08-06|website=@businessline|date=29 March 2016 |language=en}}</ref>


It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.<ref name="Business Standard India"/>
It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.<ref name="Business Standard India"/>


From 2016 to 2018, Sun Pharma launched some of its new products in the USA.<ref name="sunpharma.com"/> It launched its first branded ophthalmic product, BromSite™ in 2016.<ref>{{Cite web|last=Monday|last2=November 28|last3=Tweet|first3=2016|title=Sun Pharma Launches First Branded Ophthalmic Product in U.S.|url=http://www.ophthalmologyweb.com/1315-News/330803-Sun-Pharma-Launches-First-Branded-Ophthalmic-Product-in-U-S/|access-date=2021-08-06|website=www.ophthalmologyweb.com|language=en}}</ref> In 2017, the company launched its speciality product Odomzo.<ref>{{Cite web|last=Trivedi|first=Isha|date=2016-12-22|title=Sun Pharma to acquire Novartis’s cancer drug Odomzo for $175 mn|url=https://www.livemint.com/Companies/0dD50eq5zcAuTg60uB1qUM/Sun-Pharma-to-acquire-Novartiss-cancer-drug-Odomzo-for-175.html|access-date=2021-08-06|website=mint|language=en}}</ref> and then in 2018 another specialty product ILUMYA™ (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.<ref>{{Cite web|last=Medha|date=2018-10-25|title=New drug launched for moderate-to-severe plaque psoriasis|url=https://speciality.medicaldialogues.in/new-drug-launched-for-moderate-to-severe-plaque-psoriasis|access-date=2021-08-06|website=speciality.medicaldialogues.in|language=en}}</ref>
From 2016 to 2018, Sun Pharma launched some of its new products in the USA.<ref name="sunpharma.com"/> It launched its first branded ophthalmic product, BromSite™ in 2016.<ref>{{cite web|title=Sun Pharma Launches First Branded Ophthalmic Product in U.S.|url=http://www.ophthalmologyweb.com/1315-News/330803-Sun-Pharma-Launches-First-Branded-Ophthalmic-Product-in-U-S/|access-date=2022-05-12|website=Ophthalmology Web|language=en}}</ref> In 2017, the company launched its specialty product [[Odomzo]].<ref>{{cite web|last=Trivedi|first=Isha|date=2016-12-22|title=Sun Pharma to acquire Novartis's cancer drug Odomzo for $175 mn|url=https://www.livemint.com/Companies/0dD50eq5zcAuTg60uB1qUM/Sun-Pharma-to-acquire-Novartiss-cancer-drug-Odomzo-for-175.html|access-date=2021-08-06|website=mint|language=en}}</ref> and then in 2018 another specialty product [[Ilumya]]™ (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.<ref>{{cite web|last=Medha|date=2018-10-25|title=New drug launched for moderate-to-severe plaque psoriasis|url=https://speciality.medicaldialogues.in/new-drug-launched-for-moderate-to-severe-plaque-psoriasis|access-date=2021-08-06|website=speciality.medicaldialogues.in|language=en}}</ref>


In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence.<ref>{{Cite web|date=2018-11-27|title=Sun Pharma to acquire Japan's Pola Pharma for $1 mn; to strengthen presence in dermatology segment-Business News , Firstpost|url=https://www.firstpost.com/business/sun-pharma-to-acquire-japans-pola-pharma-for-1-mn-to-strengthen-presence-in-dermatology-segment-5619901.html|access-date=2021-08-06|website=Firstpost}}</ref> The company entered the Greater China market by partnering with China Medical System Holdings.<ref>{{Cite web|last=www.ETHealthworld.com|title=Sun Pharma arm enters pact with China Medical System - ET HealthWorld|url=https://health.economictimes.indiatimes.com/news/pharma/sun-pharma-arm-enters-pact-with-china-medical-system/69982236|access-date=2021-08-06|website=ETHealthworld.com|language=en}}</ref> And it launched a speciality product Cequa in the United States for the treatment of dry eyes.<ref>{{Cite web|title=Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the US|url=https://eyewire.news/articles/sun-pharma-launches-cequa-for-the-treatment-of-dry-eye-disease-in-the-us/|access-date=2021-08-06|website=Eyewire News|language=en-US}}</ref>
In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence.<ref>{{cite web|date=2018-11-27|title=Sun Pharma to acquire Japan's Pola Pharma for $1 mn; to strengthen presence in dermatology segment-Business News , Firstpost|url=https://www.firstpost.com/business/sun-pharma-to-acquire-japans-pola-pharma-for-1-mn-to-strengthen-presence-in-dermatology-segment-5619901.html|access-date=2021-08-06|website=Firstpost}}</ref> The company entered the Greater China market by partnering with China Medical System Holdings.<ref>{{cite web|last=www.ETHealthworld.com|title=Sun Pharma arm enters pact with China Medical System - ET HealthWorld|url=https://health.economictimes.indiatimes.com/news/pharma/sun-pharma-arm-enters-pact-with-china-medical-system/69982236|access-date=2021-08-06|website=ETHealthworld.com|language=en}}</ref> As well as launched a speciality product, [[Cequa]], in the United States for the treatment of dry eyes.<ref>{{cite web|title=Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the US|url=https://eyewire.news/articles/sun-pharma-launches-cequa-for-the-treatment-of-dry-eye-disease-in-the-us/|access-date=2021-08-06|website=Eyewire News|language=en-US}}</ref>


==SPARC==
==SPARC==
In 2007, Sun Pharma demerged its innovative R&D arm, and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. ({{NSE|SPARC}}, {{BSE|532872}}). In 2013, SPARC declared revenue of ₹873 million.<ref>{{cite web|url=http://www.moneycontrol.com/financials/sunpharmaadvancedresearchcompany/profit-loss/SPA#SPA|title=Sun Pharma Advanced Research Company Profit & Loss account, Sun Pharma Advanced Research Company Financial Statement & Accounts|website=Moneycontrol.com|access-date=2 July 2015}}</ref> SPARC focuses on new chemical entities (NCE) research and new drug delivery systems and offers an annual update<ref>{{Cite web |url=http://www.sunpharma.in/SPARC%20Investor%20Update%20Feb%2026%202014.pdf |title=Archived copy |access-date=10 April 2014 |archive-url=https://web.archive.org/web/20140413143947/http://www.sunpharma.in/SPARC%20Investor%20Update%20Feb%2026%202014.pdf |archive-date=13 April 2014 |url-status=dead |df=dmy-all }}</ref> of its pipeline (NDDS).<ref>{{cite web|url=http://sunpharma.in/index.htm|title=SUN PHARMA ADVANCED RESEARCH COMPANY|website=Sunpharma.in|access-date=2 July 2015}}</ref>
In 2007, Sun Pharma demerged its innovative R&D arm, and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. ({{NSE|SPARC}}, {{BSE|532872}}). In 2013, SPARC declared revenue of ₹873 million.<ref>{{cite web|url=http://www.moneycontrol.com/financials/sunpharmaadvancedresearchcompany/profit-loss/SPA#SPA|title=Sun Pharma Advanced Research Company Profit & Loss account, Sun Pharma Advanced Research Company Financial Statement & Accounts|website=Moneycontrol.com|access-date=2 July 2015}}</ref> SPARC focuses on [[new chemical entities]] (NCE) research and new [[drug delivery systems]] and offers an annual update<ref>{{cite web |url=http://www.sunpharma.in/SPARC%20Investor%20Update%20Feb%2026%202014.pdf |title=Investor Update on R&D Pipeline |access-date=12 May 2022 |archive-url=https://web.archive.org/web/20140413143947/http://www.sunpharma.in/SPARC%20Investor%20Update%20Feb%2026%202014.pdf |archive-date=13 April 2014 |url-status=dead |df=dmy-all }}</ref> of its pipeline (NDDS).<ref>{{cite web|url=http://sunpharma.in/index.htm|title=SUN PHARMA ADVANCED RESEARCH COMPANY|website=Sunpharma.in|access-date=2 July 2015}}</ref>


==Awards ==
==Awards ==
Sun Pharma stood second in the [[India's Most Reputed Brands]] (Pharmaceutical) list <ref>{{Cite web |url=http://economictimes.indiatimes.com/pharma/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms |title=Archived copy |access-date=18 August 2016 |archive-url=https://web.archive.org/web/20160820160335/http://economictimes.indiatimes.com/pharma/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms |archive-date=20 August 2016 |url-status=dead |df=dmy-all }}</ref> in a study conducted by BlueBytes,<ref>{{cite web|url=http://www.bluebytes.info|title=Blue Bytes|website=Bluebytes.info|access-date=19 July 2018}}</ref> a leading Media Analytics firm in association with TRA Research,<ref>{{cite web|url=http://www.trustadvisory.info|title=TRA|website=Trustadvisory.info|access-date=19 July 2018}}</ref> a brand insights organization (both a part of the Comniscient Group).
Sun Pharma stood second in the India's Most Reputed Brands (Pharmaceutical) list <ref>{{cite web |url=http://economictimes.indiatimes.com/pharma/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms |title=Lupin,Sun Pharma and Cipla amongst tops most reputed pharma brand list |access-date=18 August 2016 |archive-url=https://web.archive.org/web/20160820160335/http://economictimes.indiatimes.com/pharma/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms |archive-date=20 August 2016 |url-status=dead |df=dmy-all }}</ref> in a study conducted by BlueBytes,<ref>{{cite web|url=http://www.bluebytes.info|title=Blue Bytes|website=Bluebytes.info|access-date=19 July 2018}}</ref> a leading Media Analytics firm in association with TRA Research,<ref>{{cite web|url=http://www.trustadvisory.info|title=TRA|website=Trustadvisory.info|access-date=19 July 2018}}</ref> a brand insights organization (both a part of the Comniscient Group).
 
===2019===
 
* Listed among the [[Forbes]] "World's Best Regarded Companies"<ref name="Sun Pharma Industries"/>
 
*  CSR subsidiary Foundation for Disease Elimination and Control of India conferred with Mahatma Award for Social Good 2019<ref>{{cite web|title=2019 Recipients|url=https://www.mahatmaaward.com/india-2019|access-date=2021-08-06|website=Mahatma Award|language=en}}</ref>


'''2019:'''
* Mobile Healthcare Unit project recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum<ref>{{cite web|title=ACEF-Asian Leaders Forum and Awards|url=https://www.customerengagement.asia/winners/2019_September.html|access-date=2021-08-06|website=www.customerengagement.asia}}</ref>


1.Listed among the Forbes World’s Best Regarded companies"<ref name="Sun Pharma Industries"/>
===2020===
* Listed among the Forbes World's Best Employers 2020<ref>{{cite web|title=The World's Best Employers 2020|url=https://www.forbes.com/lists/worlds-best-employers/|access-date=2021-08-06|website=Forbes|language=en}}</ref>


2. CSR subsidiary Foundation for Disease Elimination and Control of India conferred with Mahatma Award for Social Good 2019<ref>{{Cite web|title=2019 Recipients|url=https://www.mahatmaaward.com/india-2019|access-date=2021-08-06|website=Mahatma Award|language=en}}</ref>
* Volini named in Nielsen BASES Top Breakthrough Innovation Winners India 2020 list<ref>{{cite web|title=Radhika Joshi on LinkedIn: #BASES #innovation #breakthroughinnovations {{!}} 28 comments|url=https://www.linkedin.com/posts/radhika-joshi-1214851a_bases-innovation-breakthroughinnovations-activity-6744605462500560896-Xa4W|access-date=2021-08-06|website=www.linkedin.com|language=en}}</ref>


3. Mobile Healthcare Unit project recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum<ref>{{Cite web|title=ACEF-Asian Leaders Forum and Awards|url=https://www.customerengagement.asia/winners/2019_September.html|access-date=2021-08-06|website=www.customerengagement.asia}}</ref>


'''2020:'''
===2021===
* Received the Golden Peacock Award for Corporate Social Responsibility, 2020<ref>{{Cite web|title=Institute of Directors, India on LinkedIn: GPA Results sheet for CSR & HR Excellence - 2020|url=https://www.linkedin.com/posts/iodglobal_gpa-results-sheet-for-csr-hr-excellence-activity-6785524984572858368-0Tgc|access-date=2022-02-11|website=www.linkedin.com|language=en}}</ref>


1. Listed among the Forbes World’s Best Employers 2020<ref>{{Cite web|title=The World's Best Employers 2020|url=https://www.forbes.com/lists/worlds-best-employers/|access-date=2021-08-06|website=Forbes|language=en}}</ref>
* Won the Dun & Bradstreet India Corporate Award under the Sectoral Performance-based category- Pharmaceuticals<ref>{{cite AV media |date=19 August 2021 |url=https://www.youtube.com/watch?v=6Qm3nz3wq4Y |title=Award for Sectoral Performance based category-Pharmaceuticals- Sun Pharmaceutical Industries Limited |publisher=Dun & Bradstreet India |via=[[YouTube]] |access-date=18 February 2022 |archive-url=https://web.archive.org/web/20220209121708/https://www.youtube.com/watch?v=6Qm3nz3wq4Y |archive-date=9 February 2022 |url-status=live}}</ref>


2. Volini named in Nielsen BASES Top Breakthrough Innovation Winners India 2020 list<ref>{{Cite web|title=Radhika Joshi on LinkedIn: #BASES #innovation #breakthroughinnovations {{!}} 28 comments|url=https://www.linkedin.com/posts/radhika-joshi-1214851a_bases-innovation-breakthroughinnovations-activity-6744605462500560896-Xa4W|access-date=2021-08-06|website=www.linkedin.com|language=en}}</ref>
* Bagged the Distribution Industry Award for Notable Achievements in Healthcare (DIANA) award for ‘Best New Product Introduction/Promotion’ at the Annual Healthcare Distribution Alliance Conference 2021<ref>{{cite tweet |author=HDA - Healthcare Distribution Alliance |user=HDAconnect |number=1404449331575463945 |date=14 June 2021 |title=.@SunPharma_Live wins the Best New Product Introduction or Promotion DIANA in the “Generic Pharmaceutical Products” category for Epoprostenol. https://t.co/XCYZlqLOCE |language=en |access-date=18 February 2022 |archive-url=https://web.archive.org/web/20220213221759/https://twitter.com/hdaconnect/status/1404449331575463945 |archive-date=13 February 2022 |url-status=live}}</ref>
 
* Recognized as the Best Innovative Company of the Year 2021 at Indo-American Corporate Excellence Awards<ref>{{cite tweet |author=Indo-American Chamber of Commerce |user=iaccindia |number=1448150318466752517 |date=13 October 2021 |title=Sun Pharma - The winner of ‘Excellence in Innovation’ for the year 2021. Mr. C S Muralidharan, Chief Financial Officer of Sun Pharma had collected the award for #SunPharma. #IACCIndia #CorporateAwards #AwardNight #winner #IndoUSrelation #IndoAmericanCorporateExcellenceAwards https://t.co/PxFksVw48c |language=en |access-date=18 February 2022 |archive-url=https://web.archive.org/web/20220213221753/https://twitter.com/iaccindia/status/1448150318466752517 |archive-date=13 February 2022 |url-status=live}}</ref>


==References==
==References==
{{Reflist}}
{{reflist|colwidth=30em}}
 
==External links==
*{{Official website|http://www.sunpharma.com}}


{{Nifty 200 companies}}
{{Nifty 200 companies}}
Line 103: Line 116:
[[Category:Sun Pharma| ]]
[[Category:Sun Pharma| ]]
[[Category:BSE SENSEX]]
[[Category:BSE SENSEX]]
[[Category:Companies based in Mumbai]]
[[Category:Indian brands]]
[[Category:Indian brands]]
[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies of India]]

Latest revision as of 13:37, 10 June 2022


Sun Pharmaceutical Industries Limited
Traded as
ISININE044A01036
IndustryPharmaceuticals
Founded1983; 43 years ago (1983)
Founder(s)Dilip Shanghvi
Headquarters
Mumbai
,
India
Area served
Worldwide
Key people
Dilip Shanghvi (MD)
Products
RevenueIncrease ₹343,337 million (US$4.8 billion) (2021)
Increase ₹334,981 million (US$4.7 billion) (2021)
Increase ₹29,038 million (US$410 million) (2021)
Total assetsIncrease ₹142,965 million (US$2.0 billion) (2021)
Total equityIncrease ₹2,399 million (US$34 million) (2021)
Number of employees
37,000+ (2021)
Websitesunpharma.com
Footnotes / references
[1][2]

Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe.[3] It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world,[4] with a total revenue of over US$4.5 billion as of June 2021.[5] The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.[4] Its API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budensonide and Carvedilol.[6]

History[edit | edit source]

Sun Pharmaceuticals was founded by Dilip Shanghvi in 1983 in Vapi, Gujarat, with five products to treat psychiatry ailments. Cardiology products were introduced in 1987[7] followed by gastroenterology products in 1989. Today it is ranked number one by prescriptions with nine different specialties of doctors in[8] India and a market leader in cardiology, gastroenterology, ortho,[vague] diabetology, dermatology, urology, vitamins, minerals, and nutrients.[9]

The 2014 acquisition of Ranbaxy made Sun Pharma the largest pharma company in India, the largest Indian pharma company in the US, and the 4th[4] largest specialty generic company globally.

Over 72% of Sun Pharma sales are from markets outside India, primarily in the United States. The US is the single largest market, accounting for about 30% of the company's turnover;[10] in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 44 global locations in India, the US, Asia, Africa, Australia and Europe. In the United States, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).[11]

Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company.[12]

Acquisitions and Joint Ventures[edit | edit source]

Sun Pharma has complemented growth with select acquisitions over the last two decades. In 1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and MJ Pharma's dosage plant at Halol that are both U.S. FDA approved today. In 1997, Sun Pharma acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in Chennai, mainly for their extensive gynaecology and oncology brands. Also in 1997, Sun Pharma initiated their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in Detroit.

In 1998, Sun acquired a number of respiratory brands from Natco Pharma. Other notable acquisitions include Milmet Labs and Gujarat Lyka Organics (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008). In 2010, the company acquired a large stake in Taro Pharmaceuticals,[13] amongst the largest generic dermatology companies in the US, with operations across Canada and Israel. The company currently owns ~ 69% stake in Taro, for about $260 million.[14]

In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets (other than India).[15]

In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals,[16] a dermatology device company; and generic pharma company URL Pharma [17] In 2013, the company announced an R&D joint venture for ophthalmology with the research company, Intrexon.[18]

On 6 April 2014, Sun Pharma acquired Ranbaxy in a US$4 billion landmark transaction to create the world's 5th largest specialty generic pharmaceutical company.[19]

Then Sun Pharma entered into a licensing agreement with Merck & Co. Inc. for Tildrakizumab (MK- 3222) in order to further strengthen the specialty product pipeline.[20]

To access sterile injectable capacity in the US, it acquired Pharmalucence in the US in the same year.[21]

In December 2014, the Competition Commission of India approved Sun Pharma's $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.[22][23]

In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business in Australia to strengthen its pain management portfolio.[23]

The following year Sun Pharma made some significant acquisitions, including 14 brands from Novartis in Japan to enter the Japanese market.[24]

It acquired Ocular Technologies, Sarl to strengthen its branded ophthalmic portfolio and also acquired Biosintez to enhance its presence in the Russian market.[4]

From 2016 to 2018, Sun Pharma launched some of its new products in the USA.[7] It launched its first branded ophthalmic product, BromSite™ in 2016.[25] In 2017, the company launched its specialty product Odomzo.[26] and then in 2018 another specialty product Ilumya™ (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.[27]

In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence.[28] The company entered the Greater China market by partnering with China Medical System Holdings.[29] As well as launched a speciality product, Cequa, in the United States for the treatment of dry eyes.[30]

SPARC[edit | edit source]

In 2007, Sun Pharma demerged its innovative R&D arm, and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. (NSE: SPARC, BSE: 532872). In 2013, SPARC declared revenue of ₹873 million.[31] SPARC focuses on new chemical entities (NCE) research and new drug delivery systems and offers an annual update[32] of its pipeline (NDDS).[33]

Awards[edit | edit source]

Sun Pharma stood second in the India's Most Reputed Brands (Pharmaceutical) list [34] in a study conducted by BlueBytes,[35] a leading Media Analytics firm in association with TRA Research,[36] a brand insights organization (both a part of the Comniscient Group).

2019[edit | edit source]

  • Listed among the Forbes "World's Best Regarded Companies"[5]
  • CSR subsidiary Foundation for Disease Elimination and Control of India conferred with Mahatma Award for Social Good 2019[37]
  • Mobile Healthcare Unit project recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum[38]

2020[edit | edit source]

  • Listed among the Forbes World's Best Employers 2020[39]
  • Volini named in Nielsen BASES Top Breakthrough Innovation Winners India 2020 list[40]


2021[edit | edit source]

  • Received the Golden Peacock Award for Corporate Social Responsibility, 2020[41]
  • Won the Dun & Bradstreet India Corporate Award under the Sectoral Performance-based category- Pharmaceuticals[42]
  • Bagged the Distribution Industry Award for Notable Achievements in Healthcare (DIANA) award for ‘Best New Product Introduction/Promotion’ at the Annual Healthcare Distribution Alliance Conference 2021[43]
  • Recognized as the Best Innovative Company of the Year 2021 at Indo-American Corporate Excellence Awards[44]

References[edit | edit source]

  1. ↑ "Sun Pharmaceutical Announces Fourth Quarter and Fiscal Year 2018 Results" (PDF). mypharmaproducts.store. Sun Pharmaceutical. 4 February 2019. Retrieved 4 February 2019.
  2. ↑ "Annual Report 2020-21" (PDF). Sun Pharmaceutical Industries. Retrieved 12 May 2022.
  3. ↑ Banerjee, Avishek. products-Global-Is-Local/27-12-2018-165598 "Sun Pharma: Global Is Local". BW Businessworld. Retrieved 6 August 2021. {{cite web}}: Check |url= value (help)
  4. ↑ 4.0 4.1 4.2 4.3 products-inds-4325/information/company-history "Sun Pharmaceuticals Industries Ltd". Business Standard India. Retrieved 6 August 2021. {{cite news}}: Check |url= value (help)
  5. ↑ 5.0 5.1 products-industries/ "Sun Pharma Industries". Forbes. Retrieved 6 August 2021. {{cite web}}: Check |url= value (help)
  6. ↑ products "pharma products| IBEF". www.ibef.org. Retrieved 6 August 2021. {{cite web}}: Check |url= value (help)[permanent dead link]
  7. ↑ 7.0 7.1 "Milestones & Recognitions | Sun Pharmaceutical Industries Limited". Sun Pharmaceutical Industries Ltd. Retrieved 6 August 2021.
  8. ↑ "Strategic solutions", Hospitality Marketing, Routledge, pp. 210–219, 11 January 2013, doi:10.4324/9780080938486-27, ISBN 978-0-08-093848-6, retrieved 6 August 2021{{citation}}: CS1 maint: work parameter with ISBN (link)
  9. ↑ Katja S, Ziegler (April 2019), "AWACS I (Ger)", Max Planck Encyclopedia of Comparative Constitutional Law, Oxford University Press, doi:10.1093/law-mpeccol/e542.013.542, retrieved 6 August 2021
  10. ↑ "US business remains Sun Pharma's weak spot". www.fortuneindia.com. Retrieved 6 August 2021.
  11. ↑ "Creating Lasting Value Investor Presentation - February 2014" (PDF). Archived from the original (PDF) on 13 April 2014. Retrieved 10 April 2014.
  12. ↑ "Galaxy Surfactants: financial results for the quarter and nine months ended 31 Dec 2018". Focus on Surfactants. 2019 (3): 6. March 2019. doi:10.1016/j.fos.2019.03.069. ISSN 1351-4210. S2CID 243155570.
  13. ↑ "USA – Taro Pharmaceutical Industries". Tarousa.com. Retrieved 19 July 2018.
  14. ↑ "Corporate Website: Acquisitions". Sunpharma.com. Archived from the original on 10 August 2011. Retrieved 19 July 2018.
  15. ↑ "Sun Pharmaceutical, Merck & Co call off 2011 JV: Sources". The Economic Times. Retrieved 6 August 2021.
  16. ↑ "Sun Pharma to buy U.S.-based Dusa for $230 mln". Reuters India. 8 November 2012. Retrieved 2 July 2015.
  17. ↑ Takeda Pharmaceutical Company Limited. "Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical". Takeda.com. Retrieved 2 July 2015.
  18. ↑ "Investors – Newsroom – Intrexon". Investors.dna.com. Retrieved 2 July 2015.{{cite web}}: CS1 maint: deprecated archival service (link)
  19. ↑ Reporter, B. S. (8 April 2014). "Sun Pharma buys Ranbaxy from Japan's Daiichi". Business Standard India. Retrieved 6 August 2021.
  20. ↑ "Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab". The Economic Times. Retrieved 6 August 2021.
  21. ↑ Unnikrishnan, C. H. (16 July 2014). "Sun Pharma acquires US injectables firm Pharmalucence". mint. Retrieved 6 August 2021.
  22. ↑ "CCI clears Sun Pharma-Ranbaxy deal". Reuters India. 9 December 2014. Retrieved 2 July 2015.
  23. ↑ 23.0 23.1 "UPDATE 1-India's Sun Pharma to buy Glaxo's opiates business in Australia". Reuters India. 3 March 2015. Retrieved 2 July 2015.
  24. ↑ "Sun Pharma acquires Novartis brands in Japan for $293 million". @businessline. 29 March 2016. Retrieved 6 August 2021.
  25. ↑ "Sun Pharma Launches First Branded Ophthalmic Product in U.S." Ophthalmology Web. Retrieved 12 May 2022.
  26. ↑ Trivedi, Isha (22 December 2016). "Sun Pharma to acquire Novartis's cancer drug Odomzo for $175 mn". mint. Retrieved 6 August 2021.
  27. ↑ Medha (25 October 2018). "New drug launched for moderate-to-severe plaque psoriasis". speciality.medicaldialogues.in. Retrieved 6 August 2021.
  28. ↑ "Sun Pharma to acquire Japan's Pola Pharma for $1 mn; to strengthen presence in dermatology segment-Business News , Firstpost". Firstpost. 27 November 2018. Retrieved 6 August 2021.
  29. ↑ www.ETHealthworld.com. "Sun Pharma arm enters pact with China Medical System - ET HealthWorld". ETHealthworld.com. Retrieved 6 August 2021.
  30. ↑ "Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the US". Eyewire News. Retrieved 6 August 2021.
  31. ↑ "Sun Pharma Advanced Research Company Profit & Loss account, Sun Pharma Advanced Research Company Financial Statement & Accounts". Moneycontrol.com. Retrieved 2 July 2015.
  32. ↑ "Investor Update on R&D Pipeline" (PDF). Archived from the original (PDF) on 13 April 2014. Retrieved 12 May 2022.
  33. ↑ "SUN PHARMA ADVANCED RESEARCH COMPANY". Sunpharma.in. Retrieved 2 July 2015.
  34. ↑ "Lupin,Sun Pharma and Cipla amongst tops most reputed pharma brand list". Archived from the original on 20 August 2016. Retrieved 18 August 2016.
  35. ↑ "Blue Bytes". Bluebytes.info. Retrieved 19 July 2018.
  36. ↑ "TRA". Trustadvisory.info. Retrieved 19 July 2018.
  37. ↑ "2019 Recipients". Mahatma Award. Retrieved 6 August 2021.
  38. ↑ "ACEF-Asian Leaders Forum and Awards". www.customerengagement.asia. Retrieved 6 August 2021.
  39. ↑ "The World's Best Employers 2020". Forbes. Retrieved 6 August 2021.
  40. ↑ "Radhika Joshi on LinkedIn: #BASES #innovation #breakthroughinnovations | 28 comments". www.linkedin.com. Retrieved 6 August 2021.
  41. ↑ "Institute of Directors, India on LinkedIn: GPA Results sheet for CSR & HR Excellence - 2020". www.linkedin.com. Retrieved 11 February 2022.
  42. ↑ Award for Sectoral Performance based category-Pharmaceuticals- Sun Pharmaceutical Industries Limited. Dun & Bradstreet India. 19 August 2021. Archived from the original on 9 February 2022. Retrieved 18 February 2022 – via YouTube.
  43. ↑ HDA - Healthcare Distribution Alliance [@HDAconnect] (14 June 2021). ".@SunPharma_Live wins the Best New Product Introduction or Promotion DIANA in the "Generic Pharmaceutical Products" category for Epoprostenol. t.co/XCYZlqLOCE" (Tweet). Archived from the original on 13 February 2022. Retrieved 18 February 2022 – via Twitter.
  44. ↑ Indo-American Chamber of Commerce [@iaccindia] (13 October 2021). "Sun Pharma - The winner of 'Excellence in Innovation' for the year 2021. Mr. C S Muralidharan, Chief Financial Officer of Sun Pharma had collected the award for #SunPharma. #IACCIndia #CorporateAwards #AwardNight #winner #IndoUSrelation #IndoAmericanCorporateExcellenceAwards t.co/PxFksVw48c" (Tweet). Archived from the original on 13 February 2022. Retrieved 18 February 2022 – via Twitter.

Template:BSE Sensex Template:S&P CNX Nifty companies

Retrieved from "https://en.bharatpedia.org/w/index.php?title=Sun_Pharma&oldid=338630"
Discover more